glp-1 news oct 16 2025 Drugs: Pulse Survey (U.S.) Regulating a "Miracle Drug": GLP-1

Activation of phospholipase C-beta1 via Galphaq/11 during calcium mobilization by calcitonin gene-related peptide

Prakash A, Bhatt DL

That is clinically relevant wound-healing evidence, but it involved a specific topical wound-care protocol and should not be generalized to unsupervised use

Nat Rev Immunol (2016) 16(9):55365

At least in the US, the numbers are truly staggering with c 44% of people belonging in the obese or overweight group, which could increase to 53% by the end of the decade

(Hurley & Frier, 2025) For patients, this means the first question to ask of any provider offering peptide therapy isn't "do you offer peptides" but "how are you sourcing them and what is the current regulatory status of each compound you prescribe?" A provider still listing Category 2 compounds as standard menu offerings without discussing compounding compliance is telling you something important about their regulatory literacy